ATANIS Biotech, a Swiss biotechnology company specializing in functional allergy diagnosis, announced the successful completion of a significant capital increase. iXLife, a French venture capital fund, co-led the round with US-based AllerFund, the first and only venture capital firm focused on social impact in the food allergy space. Additional investments came from experienced private biotech […]
Kellerhals Carrard has reorganised and strengthened its Life Sciences team. It is now fully integrated into the value chain of its clients in the pharmaceutical, medical technology, health and nutrition sectors and is led by
Wenger Vieli advised TriNetX, a portfolio company of Carlyle, on its acquisition of Clinerion, a Swiss-based subsidiary of Norstella. Through a new multi-faceted, long-term agreement Norstella with Clinerion and TriNetX expand the world’s leading
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 mio (approx. USD 112 mio). The round was co-led by the European healthcare focused
The German life science and medtech private equity firm SHS Capital has made a EUR 10 million investment in Simulands, a Swiss manufacturer of simulation devices for medical training of cardiovascular interventions. The investment aims to
Vifor Pharma Group closed its divestment transaction regarding its finished drug product manufacturing business with facilities in Fribourg, Ettingen (both in Switzerland) and Lisbon (Portugal) to CordenPharma, a full-service Contract Development & Manufacturing Organisation (CDMO)
The team was led by Stefan Kohler (IP / Life Sciences - pictured) and Christoph Niederer (Tax).
The VISCHER team, led by partner Robert Bernet (Corporate / M & A - pictured) includes Peter Kühn (Counsel, Corporate / M & A), Florian Kambor (Junior Associate, Corporate / M & A) and Christian Wyss (Partner, IP).
The team was led by partner Emanuel Dettwiler (Corporate/M&A - pictured) and comprised senior associate Sophie Holdt (Corporate/M&A).